2023
Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment
de Oliveira M, de Barros P, de Mathis M, Boavista R, Chacon P, Echevarria M, Ferrão Y, de Queiroz Vattimo E, Lopes A, Torres A, Diniz J, Fontenelle L, do Rosário M, Shavitt R, Miguel E, da Silva R, da Conceição Costa D. Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment. Brazilian Journal Of Psychiatry 2023, 45: 146-161. PMID: 36749887, PMCID: PMC10154009, DOI: 10.47626/1516-4446-2022-2891.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsAdult obsessive-compulsive disorderObsessive-compulsive disorderPharmacological treatmentReuptake inhibitorsEvidence-based pharmacological interventionsFirst-line pharmacological treatmentAmerican Psychiatric Association guidelinesEvidence-based pharmacological treatmentFirst-line treatmentNorepinephrine reuptake inhibitorsPrimary outcome measureSerotonin reuptake inhibitorsGlutamate-modulating agentsHigh-quality evidenceAmerican Heart AssociationLevel of evidenceTreatment of OCDBrazilian Research ConsortiumAdult patientsHeart AssociationTolerable dosesAssociation guidelinesTreatment recommendationsPharmacological interventions
2022
Associations of medication with subcortical morphology across the lifespan in OCD: Results from the international ENIGMA Consortium
Ivanov I, Boedhoe PSW, Abe Y, Alonso P, Ameis SH, Arnold PD, Balachander S, Baker JT, Banaj N, Bargalló N, Batistuzzo MC, Benedetti F, Beucke JC, Bollettini I, Brem S, Brennan BP, Buitelaar J, Calvo R, Cheng Y, Cho KIK, Dallaspezia S, Denys D, Diniz JB, Ely BA, Feusner JD, Ferreira S, Fitzgerald KD, Fontaine M, Gruner P, Hanna GL, Hirano Y, Hoexter MQ, Huyser C, Ikari K, James A, Jaspers-Fayer F, Jiang H, Kathmann N, Kaufmann C, Kim M, Koch K, Kwon JS, Lázaro L, Liu Y, Lochner C, Marsh R, Martínez-Zalacaín I, Mataix-Cols D, Menchón JM, Minuzzi L, Morer A, Morgado P, Nakagawa A, Nakamae T, Nakao T, Narayanaswamy JC, Nurmi EL, Oh S, Perriello C, Piacentini JC, Picó-Pérez M, Piras F, Piras F, Reddy YCJ, Manrique DR, Sakai Y, Shimizu E, Simpson HB, Soreni N, Soriano-Mas C, Spalletta G, Stern ER, Stevens MC, Stewart SE, Szeszko PR, Tolin DF, van Rooij D, Veltman DJ, van der Werf YD, van Wingen GA, Venkatasubramanian G, Walitza S, Wang Z, Watanabe A, Wolters LH, Xu X, Yun JY, Zarei M, Zhang F, Zhao Q, Jahanshad N, Thomopoulos SI, Thompson PM, Stein DJ, van den Heuvel OA, O'Neill J, Group T, Poletti S, Fridgeirsson E, Ikuta T, de Wit S, Vriend C, Kasprzak S, Kuno M, Takahashi J, Miguel E, Shavitt R, Hough M, Pariente J, Ortiz A, Bertolín S, Real E, Segalàs C, Moreira P, Sousa N, Narumoto J, Yamada K, Tang J, Fouche J, Kim T, Choi S, Ha M, Park S. Associations of medication with subcortical morphology across the lifespan in OCD: Results from the international ENIGMA Consortium. Journal Of Affective Disorders 2022, 318: 204-216. PMID: 36041582, DOI: 10.1016/j.jad.2022.08.084.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderUnmedicated patientsOlder adultsAssociation of medicationVolumes of putamenSubcortical brain structuresReuptake inhibitorsVentricular hypertrophyHippocampal atrophyMedicated patientsPsychotropic medicationsTherapeutic responseHippocampal volumeStriatal volumeSubcortical nucleiPatientsPsychotic disordersAntipsychoticsSubcortical morphologyStructural MRINormal agingBrain structuresBenzodiazepinesOCD patientsENIGMA consortium
2019
Use of Mental Health Services by Children With Mental Disorders in Two Major Cities in Brazil
Fatori D, Salum G, Rohde L, Pan P, Bressan R, Evans-Lacko S, Polanczyk G, Miguel E, Graeff-Martins A. Use of Mental Health Services by Children With Mental Disorders in Two Major Cities in Brazil. Psychiatric Services 2019, 70: 337-341. PMID: 30651056, DOI: 10.1176/appi.ps.201800389.Peer-Reviewed Original ResearchConceptsMental health servicesMental disordersUnmet needHealth servicesHigh Risk Cohort StudyCombination of psychotherapyMental health treatmentChildren ages 6Cohort studyHealth treatmentCommunity studyAge 6DisordersHealth careLifetime useWhite childrenChildrenHigh rateTreatmentCurrent studyPorto AlegreSao PauloMedicationsPsychotherapyDiagnosisTreatments used for obsessive–compulsive disorder—An international perspective
Brakoulias V, Starcevic V, Albert U, Arumugham S, Bailey B, Belloch A, Borda T, Dell'Osso L, Elias J, Falkenstein M, Ferrao Y, Fontenelle L, Jelinek L, Kalogeraki L, Kay B, Laurito L, Lochner C, Maina G, Marazziti D, Martin A, Matsunaga H, Miguel E, Morgado P, Mourikis I, Pasquini M, Rivera R, Potluri S, Reddy J, Riemann B, do Rosario M, Shavitt R, Stein D, Viswasam K, Wang Z, Fineberg N. Treatments used for obsessive–compulsive disorder—An international perspective. Human Psychopharmacology Clinical And Experimental 2019, 34: e2686. PMID: 30628745, DOI: 10.1002/hup.2686.Peer-Reviewed Original Research
2016
International prescribing practices in obsessive–compulsive disorder (OCD)
Brakoulias V, Starcevic V, Belloch A, Dell'Osso L, Ferrão Y, Fontenelle L, Lochner C, Marazziti D, Martin A, Matsunaga H, Miguel E, Reddy Y, do Rosário M, Shavitt R, Sundar A, Stein D, Viswasam K. International prescribing practices in obsessive–compulsive disorder (OCD). Human Psychopharmacology Clinical And Experimental 2016, 31: 319-324. PMID: 27271200, DOI: 10.1002/hup.2541.Peer-Reviewed Original ResearchNEUROPSYCHOLOGICAL PREDICTORS OF TREATMENT RESPONSE TO COGNITIVE BEHAVIORAL GROUP THERAPY IN OBSESSIVE–COMPULSIVE DISORDER
Braga D, Abramovitch A, Fontenelle L, Ferrão Y, Gomes J, Vivan A, Ecker K, Bortoncello C, Mittelman A, Miguel E, Trentini C, Cordioli A. NEUROPSYCHOLOGICAL PREDICTORS OF TREATMENT RESPONSE TO COGNITIVE BEHAVIORAL GROUP THERAPY IN OBSESSIVE–COMPULSIVE DISORDER. Depression And Anxiety 2016, 33: 848-861. PMID: 27100799, DOI: 10.1002/da.22509.Peer-Reviewed Original ResearchConceptsCognitive-behavioral group therapyObsessive-compulsive disorderBehavioral group therapyNeuropsychological test performanceTest performanceNeuropsychological domainsCBGT groupGroup therapyOCD patientsNeuropsychological outcome measuresNeuropsychological predictorsNeuropsychological functioningNeuropsychological measuresOCD symptomsNeurocognitive functionDepression symptomsTreatment respondersTreatment responseParticipantsAvailable researchInconsistent resultsDisordersPredictorsAnxietyMeasuresPrevalence and correlates of electroconvulsive therapy delivery in 1001 obsessive-compulsive disorder outpatients
dos Santos-Ribeiro S, Lins-Martins N, Frydman I, do Rosário M, Ferrão Y, Shavitt R, Yücel M, Miguel E, Fontenelle L. Prevalence and correlates of electroconvulsive therapy delivery in 1001 obsessive-compulsive disorder outpatients. Psychiatry Research 2016, 239: 145-148. PMID: 27137976, DOI: 10.1016/j.psychres.2016.03.020.Peer-Reviewed Original ResearchConceptsElectroconvulsive therapyObsessive-compulsive disorderOCD patientsHigher global severitySerotonin reuptake inhibitorsObsessive-compulsive disorder outpatientsContamination/washing symptomsRates of psychosisDifferent specialized centersAdequate trialReuptake inhibitorsSpecialized centersGlobal severityGreater suicidalityDisorder outpatientsTherapy deliveryTerms of responseAssessment BatteryPatientsOCD symptomsSymptomsWashing symptomsAntipsychoticsOutpatientsTherapy
2014
Musical obsessions: A comprehensive review of neglected clinical phenomena
Taylor S, McKay D, Miguel E, De Mathis M, Andrade C, Ahuja N, Sookman D, Kwon J, Huh M, Riemann B, Cottraux J, O’Connor K, Hale L, Abramowitz J, Fontenelle L, Storch E. Musical obsessions: A comprehensive review of neglected clinical phenomena. Journal Of Anxiety Disorders 2014, 28: 580-589. PMID: 24997394, DOI: 10.1016/j.janxdis.2014.06.003.Peer-Reviewed Original ResearchAdolescentAdultAgedAged, 80 and overAntipsychotic AgentsAvoidance LearningChildCognitive Behavioral TherapyDiagnosis, DifferentialFearFemaleHallucinationsHumansImaginationMaleMiddle AgedModels, PsychologicalMusicObsessive BehaviorObsessive-Compulsive DisorderSelective Serotonin Reuptake InhibitorsYoung Adult
2013
The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder
Diniz J, Costa D, Cassab R, Pereira C, Miguel E, Shavitt R. The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder. Journal Of Psychopharmacology 2013, 28: 603-611. PMID: 24288238, DOI: 10.1177/0269881113512042.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive Agents, Second-GenerationAntidepressive Agents, TricyclicAntipsychotic AgentsBody Dysmorphic DisordersBrazilClomipramineComorbidityDrug Therapy, CombinationFemaleFluoxetineHumansMaleObsessive-Compulsive DisorderProspective StudiesQuetiapine FumarateRisk FactorsTreatment OutcomeConceptsBody dysmorphic disorderComorbid body dysmorphic disorderPharmacological trialsDysmorphic disorderAdult obsessive-compulsive disorder (OCD) patientsSequential treatment strategyObsessive-compulsive disorder patientsSequential treatmentFluoxetine monotherapyClinical characteristicsObsessive-compulsive disorderInitial severityTreatment strategiesDisorder patientsTreatment groupsPatientsWorse responseBDD patientsEffects of sexGEE modelTrialsDisordersSequential trialsWeeksType of augmentation
2011
A Double-Blind, Randomized, Controlled Trial of Fluoxetine Plus Quetiapine or Clomipramine Versus Fluoxetine Plus Placebo for Obsessive-Compulsive Disorder
Diniz J, Shavitt R, Fossaluza V, Koran L, de Bragança Pereira C, Miguel E. A Double-Blind, Randomized, Controlled Trial of Fluoxetine Plus Quetiapine or Clomipramine Versus Fluoxetine Plus Placebo for Obsessive-Compulsive Disorder. Journal Of Clinical Psychopharmacology 2011, 31: 763-768. PMID: 22020357, DOI: 10.1097/jcp.0b013e3182367aee.Peer-Reviewed Original ResearchConceptsY-BOCS scoresFluoxetine groupTreatment regimenSelective serotonin reuptake inhibitorsPlacebo-controlled trialSevere adverse eventsSerotonin reuptake inhibitorsMain outcome measuresObsessive-compulsive disorder patientsCompulsive Scale scoresYale-Brown ObsessiveFluoxetine monotherapyAdverse eventsReuptake inhibitorsObsessive-compulsive disorderPrimary diagnosisOutcome measuresDisorder patientsScale scoreFluoxetineMental disordersQuetiapinePatientsStatistical ManualClomipramine
2009
Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial
Diniz J, Shavitt R, Pereira C, Hounie A, Pimentel I, Koran L, Dainesi S, Miguel E. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. Journal Of Psychopharmacology 2009, 24: 297-307. PMID: 19164490, DOI: 10.1177/0269881108099423.Peer-Reviewed Original ResearchObsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol
R. A, Hounie A, Sampaio A, Arrais J, Miguel E, Elkis H. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol. Comprehensive Psychiatry 2009, 50: 437-442. PMID: 19683614, DOI: 10.1016/j.comppsych.2008.11.005.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsAntipsychotic AgentsClozapineComorbidityDiagnostic and Statistical Manual of Mental DisordersDrug Therapy, CombinationFemaleHaloperidolHumansInterview, PsychologicalMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychometricsSchizophreniaYoung AdultConceptsObsessive-compulsive disorderObsessive-compulsive symptomsSchizophrenia patientsPrevalence of OCDSchizophrenia rating scalesPresence of OCSPrevalence of patientsUse of clozapineUse of antidepressantsClinical Global ImpressionPANSS total scoreCross-sectional studyStructured Clinical InterviewHigher severity scoresNegative Syndrome ScaleHigher severityYale-Brown ObsessiveGlobal ImpressionSeverity scorePatientsClozapineClinical InterviewHaloperidolSchizophrenia symptomsSyndrome Scale
2007
Resistência e refratariedade no transtorno obsessivo-compulsivo
Ferrão Y, Diniz J, Lopes A, Shavitt R, Greenberg B, Miguel E. Resistência e refratariedade no transtorno obsessivo-compulsivo. Brazilian Journal Of Psychiatry 2007, 29: s66-s76. PMID: 18172943, DOI: 10.1590/s1516-44462006005000059.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsAntipsychotic AgentsBehavior TherapyClinical Trials as TopicCombined Modality TherapyDrug ResistanceDrug ToleranceFamily RelationsHumansMeta-Analysis as TopicObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychotherapySelective Serotonin Reuptake InhibitorsConceptsObsessive-compulsive disorder patientsObsessive-compulsive disorderTherapeutic alternativeDisorder patientsConventional treatmentEffective therapeutic alternativeCompulsive disorder patientsAvailable treatmentsTreatment responseClinical challengeTreatment resistanceSymptom remissionAdequate treatmentPatient sufferingPatientsCurrent conceptsRemissionMore studiesTreatmentDisordersSignificant numberLiterature reviewUnanswered questionsExtrinsic factors
1994
Tourette's Disorder and Related Problems: A Review and Update
Coffey B, Miguel E, Savage C, Rauch S. Tourette's Disorder and Related Problems: A Review and Update. Harvard Review Of Psychiatry 1994, 2: 121-132. PMID: 9384893, DOI: 10.3109/10673229409017128.Peer-Reviewed Original ResearchConceptsTourette's disorderSerotonin reuptake inhibitorsNonmedication approachesNeuroleptic treatmentObsessive-compulsive disorderPsychiatric comorbidityVariety of agentsBasal gangliaModerate symptomsTricyclic antidepressantsCorticothalamic circuitVocal ticsLongitudinal followSevere symptomsStudy of childrenPsychiatric symptomatologyNeurological originMultifaceted conditionClinical settingObsessive-compulsive symptomsSymptomsDisordersNeuropsychological studiesFurther investigationTreatment